"Amarantus recently received an independent third-
Post# of 30028
(Total Views: 469)
Posted On: 09/04/2018 8:53:36 PM
"Amarantus recently received an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million."
This doesn't include any of the other indications including this one:
"In addition, there has been a renewed focus on evaluating a potential secondary indication for eltoprazine that is related to Alzheimer's disease. The team has made substantial progress, in consultation with our Alzheimer's SAB, in refining the target product profile for eltoprazine in that area. Further information on our plans in this area will be provided in the second half of 2018."
This doesn't include any of the other indications including this one:
"In addition, there has been a renewed focus on evaluating a potential secondary indication for eltoprazine that is related to Alzheimer's disease. The team has made substantial progress, in consultation with our Alzheimer's SAB, in refining the target product profile for eltoprazine in that area. Further information on our plans in this area will be provided in the second half of 2018."
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼